An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorEmory University

About this trial

This clinical trial tests an individualized online home-based exercise program in gynecologic cancer survivors and its impact on gut microbiome (the bacteria and microorganisms that live in the digestive system) and symptoms such as pain, fatigue, sleep disturbance, depression, and cognitive impairment. These symptoms can significantly reduce the quality of life (QoL) and survival rate in this cancer population. Thus, promoting physical activity among cancer survivors may help mitigate these severe symptoms. Using online platforms such as Zoom can help participants access an individualized exercise program that meets their specific needs to engage in physical activity and decrease their symptom burden. Home-based exercise, by providing self-chosen time and location and low costs, can address some barriers to physical activity for cancer survivors. An individualized online home-based exercise program may be feasible, and may improve symptoms and quality of life in gynecologic cancer survivors.

Eligibility criteria

Qualifiers

Women aged ≥ 18 years old

Previously diagnosed with gynecologic cancer (e.g., uterine, ovarian, cervical)

Completed cancer treatment (chemotherapy or chemoradiation)

Able to read and speak English

Disqualifiers

History of metastatic or other primary cancer

Serious mental health conditions (e.g., bipolar disorder, schizophrenia, major depression)

Certain chronic diseases (e.g., muscular-skeletal diseases that limit mobility, autoimmune diseases, uncontrolled diabetes, hypertension, renal disease (creatinine > 2.5 mg/dL)

Unable to read/speak English

Trial design

Treatments tested in this trial

  • Exercise Intervention
  • Functional Assessment
  • Medical Device Usage and Evaluation
  • Questionnaire Administration
  • Supportive Care

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Emory University

Lead sponsor

National Cancer Institute (NCI)

Collaborator